

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Addiction	Aldehyde dehydrogenase 2 family mitochondrial (ALDH2)	<p><i>In vitro</i> and rat studies suggest that inhibiting ALDH2 could help treat cocaine addiction and prevent addiction relapse. In a rat model of cocaine addiction and relapse, a selective ALDH2 inhibitor, CVT-10216, reduced cocaine-seeking and relapse behavior compared with vehicle control. Gilead Sciences Inc. plans to continue preclinical testing of CVT-10216 to treat cocaine addiction.</p> <p>Catalyst Pharmaceutical Partners Inc. has the γ-aminobutyric acid transaminase (GABA-T) inhibitors vigabatrin (CPP-109) and CPP-115 in Phase II and preclinical testing, respectively, to treat cocaine addiction.</p> <p>Embera NeuroTherapeutics Inc.'s EMB 001, an oral combination consisting of two undisclosed generic drugs, is in Phase Ib testing to treat cocaine addiction.</p> <p>SciBX 3(33); doi:10.1038/scibx.2010.1015 Published online Aug. 26, 2010</p>	Patent and licensing status undisclosed	<p>Yao, L. <i>et al. Nat. Med.</i>; published online Aug. 22, 2010; doi:10.1038/nm.2200</p> <p>Contact: Lina Yao, Gilead Sciences Inc., Palo Alto, Calif. e-mail: lina.yao@gilead.com</p>